(Q33560379)

28 July 2017

1 reference

title

Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections (English)

1 reference

28 July 2017

1 reference

Benfield P

1

1 reference

28 July 2017

Chrisp P

series ordinal

2

1 reference

28 July 2017

publication date

1 June 1992

1 reference

28 July 2017

1 reference

28 July 2017

volume

1

1 reference

28 July 2017

issue

6

1 reference

28 July 2017

page(s)

443-459

1 reference

Prospective study comparing imipenem-cilastatin with clindamycin and gentamicin for the treatment of serious surgical infections

28 July 2017

cites work

1 reference

12 December 2020

Improved localization and survival in patients with intraabdominal abscesses

1 reference

12 December 2020

Imipenem versus tobramycin--antianaerobe antibiotic therapy in intra-abdominal infections.

1 reference

12 December 2020

Imipenem/cilastatin vs. gentamicin/clindamycin for the treatment of moderate to severe infections in hospitalized patients.

1 reference

12 December 2020

Incidence and significance of intraperitoneal aerobic and anaerobic bacteria

1 reference

12 December 2020

Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services

1 reference

12 December 2020

The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients

1 reference

12 December 2020

Imipenem (N-F-thienamycin) versus netilmicin plus clindamycin. A controlled and randomized comparison in intra-abdominal infections

1 reference

12 December 2020

Management of Anaerobic Infections

1 reference

12 December 2020

Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin

1 reference

12 December 2020

[Study of the intraperitoneal penetration of imipenem/cilastatin in acute peritonitis with perforation]

1 reference

12 December 2020

Imipenem therapy for perforated and gangrenous appendicitis.

1 reference

12 December 2020

Therapy of mixed anaerobic-aerobic infections. Lessons from studies of intra-abdominal sepsis

1 reference

12 December 2020

Antibiotic trials in intra-abdominal infections. A critical evaluation of study design and outcome reporting.

1 reference

12 December 2020

Imipenem monotherapy versus combination therapy in the management of mixed bacterial infection: a critical appraisal

1 reference

12 December 2020

What is the cost of nephrotoxicity associated with aminoglycosides?

1 reference

12 December 2020

Pharmacoeconomics of antibacterial treatment

1 reference

12 December 2020

1 reference

12 December 2020

Imipenem/cilastatin in the treatment of intraabdominal infections: a review of worldwide experience

1 reference

12 December 2020

Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections.

1 reference

12 December 2020

Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis.

1 reference

12 December 2020

Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Report from a Scandinavian Study Group

1 reference

12 December 2020

Determinants of death in patients with intraabdominal abscess

1 reference

12 December 2020

Human and non-financial costs of hospital-acquired infection

1 reference

12 December 2020

Anaerobes survive in clinical specimens despite delayed processing

1 reference

12 December 2020

Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination

1 reference

12 December 2020

Pharmacokinetics of imipenem in patients undergoing major colon surgery.

1 reference

12 December 2020

Factors affecting the choice of antibiotics in mixed infections

1 reference

12 December 2020

Enhancement of growth of aerobic and facultative bacteria in mixed infections with Bacteroides species

1 reference

12 December 2020

Treatment of acute bacterial peritonitis: a trial of imipenem/cilastatin against ampicillin-metronidazole-gentamicin

1 reference

12 December 2020

Randomized comparison of imipenem/cilastatin and ceftazidime in the empiric therapy of severe abdominal infections. A multicenter study

1 reference

12 December 2020

Antimicrobial therapy. Cost-benefit considerations

1 reference

12 December 2020

Synergistic effect of bacteroides, Clostridium, Fusobacterium, anaerobic cocci, and aerobic bacteria on mortality and induction of subcutaneous abscesses in mice

1 reference

12 December 2020

Immune response in patients with intraabdominal infections treated with imipenem. Swedish Study Group

1 reference

12 December 2020

A proposed classification of intra-abdominal infections. Stratification of etiology and risk for future therapeutic trials

1 reference

12 December 2020

Cost of individualizing aminoglycoside dosage regimens

1 reference

12 December 2020

Imipenem/cilastatin as monotherapy in severe infections: comparison with cefotaxime in combination with metronidazole and cloxacillin. Report from a Norwegian Study Group

1 reference

12 December 2020

Imipenem/cilastatin versus aminoglycoside plus amoxicillin plus clindamycin in the treatment of serious postoperative infections

1 reference

12 December 2020

Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement

1 reference

12 December 2020

Microbiological and clinical aspects on intraabdominal infections

1 reference

12 December 2020

Imipenem/cilastatin versus gentamicin/clindamycin: a cost effectiveness study

1 reference

12 December 2020

Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections

1 reference

12 December 2020

APACHE II: a severity of disease classification system

1 reference

12 December 2020

Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy

1 reference

12 December 2020

10.2165/00019053-199201060-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1004936657

0 references

1 reference